Valora Therapeutics Secures $30M Seed Funding to Advance Novel Glyco-Immune Therapies Based on Nobel Prize-Winning Science

Nov 20, 2024 22:00 CST Updated 22:00

Valora Therapeutics

Innovative Immunotherapy Researcher

November 20, Santiago,Valora Therapeutics, aValora Therapeutics Inc., a biotechnology company pioneering new approaches in immunotherapy, announced the completion of a $30 million seed funding round. The round was co-led by top investment groups Avalon BioVentures, Bregua Corporation, and TigerGene. Avalon Bioventures is recognized for its expertise in supporting innovative biotechnology companies, having been committed to nurturing groundbreaking life science companies from inception to exit.Alexandria Venture InvestmentsAnd Correlation Ventures participated in the follow-up investment. This significant investment will drive the development of Valora's proprietary AbLec platform to advance novel immunotherapies.

Valora'sAbLec（Antibody-Lectin chimera/Antibody Agglutinin ChimeraThe platform is expected to provide new perspectives for restoring appropriate immune capacity. By precisely targeting specific sugar molecules on cells, AbLecs modulate glyco-immune checkpoints, which are key control points of the body's immune response.

Dr. Carolyn Bertozzi

This innovative approach holds tremendous potential for developing first-class treatments in oncology, autoimmune diseases, and other therapeutic fields. Valora Therapeutics has obtained the exclusive licensing rights for AbLec™ technology from Stanford University. It builds upon the work of the 2022 Nobel Prize in Chemistry winner and world leader in glycobiology.Dr. Carolyn BertozziAnd the current Assistant Professor of Biological Engineering and Chemical Engineering at MITDr. Jessica StarkBuilding on the transformative work conducted at Stanford Labs. Dr. Carolyn Bertozzi and Dr. Jessica Stark are both scientific founders and advisors of Valora Therapeutics.

Dr. Miguel Garcia Guzman, CEO of Valora Therapeutics, stated:"We are deeply honored to collaborate with renowned investors and Valora’s scientific founders, Dr. Carolyn Bertozzi and Dr. Jessica Stark, in developing the AbLec platform as a groundbreaking approach for next-generation immunomodulators. This funding enables us to accelerate our R&D efforts, optimize the AbLec platform, and advance AbLec therapies into clinical trials. We are incredibly proud of the work being done at Valora and are profoundly grateful for the support from our investors."

Dr. Jessica Stark

The AbLec platform represents a significant leap forward in harnessing glycoimmunology and unlocking new paradigms in immunotherapy.The seed funding will enable Valora to further explore and develop the full potential of the AbLec platform, validate specific mechanisms of action, and advance lead molecules into preclinical development.Valora Therapeutics Inc. has established R&D operations at the Avalon BioVentures accelerator in San Diego, California, providing a supportive ecosystem comprised of biotechnology experts and resources.

Follow the official account below to explore the world with you!